-In microgravity (µG) humans have marked changes in body fluids, with a combination of an overall fluid loss and a redistribution of fluids in the cranial direction. We investigated whether interstitial pulmonary edema develops as a result of a headward fluid shift or whether pulmonary tissue fluid volume is reduced as a result of the overall loss of body fluid. We measured pulmonary tissue volume (Vti), capillary blood flow, and diffusing capacity in four subjects before, during, and after 10 days of exposure to µG during spaceflight. Measurements were made by rebreathing a gas mixture containing small amounts of acetylene, carbon monoxide, and argon. Measurements made early in flight in two subjects showed no change in Vti despite large increases in stroke volume (40%) and diffusing capacity (13%) consistent with increased pulmonary capillary blood volume. Late inflight measurements in four subjects showed a 25% reduction in Vti compared with preflight controls (P Ͻ 0.001). There was a concomittant reduction in stroke volume, to the extent that it was no longer significantly different from preflight control. Diffusing capacity remained elevated (11%; P Ͻ 0.05) late in flight. These findings suggest that, despite increased pulmonary perfusion and pulmonary capillary blood volume, interstitial pulmonary edema does not result from exposure to µG. spaceflight; zero gravity; acetylene rebreathing experiments TWO OF THE BEST DOCUMENTED physiological responses to weightlessness ever since the early manned spaceflights are the cephalad shift of bodily fluids and the net loss of body weight. There are variable results concerning the amplitude of these changes and their dependence on time spent in flight and recovery postflight [see Norsk and Epstein (12) for review]. On the basis of the cephalad fluid shift, together with a postulated increase in central venous pressure in microgravity (µG), predictions for manned spaceflight included a risk for interstitial pulmonary edema (14) . The loss of body weight has been associated with loss in bodily fluids, including interstitial fluid and plasma volume, as well as loss of a so-called lean body mass and fat components (10) . The contribution of different body compartments to the overall body fluid deficit has been estimated by an electrical impedance method that showed a loss of fluid in lower extremities (4) . Simultaneous ultrasonic measurements of soft tissue thickness on the tibia and on the forehead in the same subjects showed similar results (9) .
On the one hand, one might expect to see a marked increase in pulmonary tissue volume (Vti) early in spaceflight caused by a headward shift in body fluids (12) , by an increase in pulmonary capillary blood volume (15) , and by any interstitial pulmonary edema that may have occurred (14) . On the other hand, the overall loss of body fluids (12) , and the suggestion that lung interstitial tissue has a lower compliance for fluid accumulation than do some other body tissues (e.g., muscle; see Ref. 11) , may result in a decrease in Vti.
In the present study, we report the first measurement of Vti in weightlessness, obtained by means of the inert soluble gas-rebreathing method. As well as Vti, which incorporates pulmonary capillary blood volume, the acetylene (C 2 H 2 )-rebreathing tests performed by four astronauts during the 10-day Spacelab-D2 mission, also allowed computation of cardiac output (Q c) and stroke volume (SV). The latter parameters have been obtained in space before, both from using nitrous oxide rebreathing tests performed during the SLS-1 mission (15) and from echocardiographic (ECG) measurements during the STS51-D mission (6) . From the carbon monoxide (CO)-rebreathing traces, we also calculated CO-diffusing capacity (DL CO ). Q c, SV, and DL CO showed marked increases after only ϳ24 h in µG and trends that are consistent with previous results obtained during the SLS-1 mission covering a comparable period of sustained µG. In contrast, we observed no significant change in Vti after ϳ24 h in µG and a 25% decrease with respect to ground (1-G) control by the end of the 10-day exposure to µG, with a slow recovery postflight.
MATERIALS AND METHODS

Equipment.
A dedicated respiratory-monitoring system (Innovision, Odense, Denmark) had been developed for the European Space Agency specifically for this flight. It was part of Anthrorack, a comprehensive laboratory facility for human physiology studies. Basic features of the respiratory monitoring system were described earlier (19) . Briefly, it consisted of a quadrupole mass spectrometer for gas analysis and a respiratory valve unit from which the astronaut could either breathe cabin air through non-rebreathing valves or could rebreathe from a 4-liter bag. A manually operated rotary valve permitted the subject to switch between these two breathing modes. Volumes dispensed into the rebreathing bag were calibrated pre-and postflight with a waterdisplacement spirometer.
The two gas mixtures used for rebreathing experiments contained an inert blood-and tissue-soluble component (C 2 H 2 ), an inert insoluble component [argon (Ar)], and a hemoglobinspecific component (CO). The isotopic C 18 O (molecular weight 30) was chosen to permit analysis of CO in the presence of N 2 (molecular weight 28) by using a mass spectrometer. The two rebreathing mixtures differed in their O 2 content with the intent of being able to separate membrane and capillary blood volume components of diffusing capacity. The actual gas composition of the two gas mixtures was 0.6% C 2 H 2 -0.3% C 18 O-5% Ar, and either a mixture of 45% O 2 and balance N 2 (low-O 2 mixture) or a mixture of 5% He-3% SF 6 -86.1% O 2 (high-O 2 mixture). In addition, calibration mixtures for the mass spectrometer were carried on board, and the mass spectrometer was calibrated and corrected for cross talk daily. In the Spacelab cabin, nominal conditions were normobaric and normoxic.
Experimental procedures. The resting subject sat upright on a stool or on a cycle ergometer and performed the rebreathing tests as part of an ϳ60-min protocol. Maneuvers requiring the inhalation of blood-soluble gases were always separated by at least 10 min from maneuvers that did not include soluble gas. After having initiated a semiautomatic procedure to rinse and fill the bag with 1.8-2.2 liters rebreathing gas, depending on the subject's total lung capacity (TLC), the subject donned a noseclip and blew into the respiratory valve unit to eliminate any soluble gases that might have remained in the dead space from the rinsing procedure. He then took a few normal breaths with the valve in the non-rebreathing mode and switched the valves to rebreathe the full bag volume eight times from functional residual capacity (FRC) within ϳ20 s.
The rebreathing experiments were performed by the same four subjects as those previously reported (19) , with age, height, and weight ranging from 37 to 47 yr, from 1.74 to 1.89 m, and from 81 to 97 kg, respectively. Preflight control sessions were performed 138 and 56 days before launch. In-flight experiments during the 10-day Spacelab mission were performed by two subjects on days 1 or 2 (22-27 h after the onset of µG) and by the four subjects on days 9 or 10 (within a time span of 24 h for all four subjects). These two in-flight sessions are subsequently referred to as early and late in-flight measurements, respectively. Postflight ground measurements were performed on days 2, 4, and 9 after flight in all subjects (Rϩ2, Rϩ4, Rϩ9, respectively). Table 1 shows the distribution of rebreathing tests performed by each of the four astronauts with low-O 2 and high-O 2 rebreathing gas.
Data analysis. Gases were calibrated by using a two-point linear calibration determined from measurement of two calibration gases. In addition, C 18 O (molecular weight 30) was corrected for cross talk from the mass spectrometer spectrum peaks of N 2 (molecular weight 28) and O 2 (molecular weight 32). This was done by using two C 18 O-free gas mixtures with different O 2 and N 2 composition, i.e., air (essentially 78% N 2 and 21% O 2 ) and a hyperoxic gas mixture (essentially 0% N 2 and 90% O 2 ), with tracer concentrations of He and SF 6 used for washout tests. Volume was calibrated by using flow signals obtained from five 3-liter syringe strokes performed at different speeds. Synchronization of gas signals with all other signals [flow, volume, mouthpiece pressure, electrocardiogram (ECG)] was done by having the subject produce a rapid expiration rich in CO 2 so that a delay time between the resulting mouthpiece pressure and CO 2 increases could be determined.
After calibration of all gases and proper synchronization with the other signals, the rebreathing tests were analyzed by using a dedicated rebreathing-analysis program that determined FRC, Vti, Q c, and DL CO . Q c was determined by the method of Sackner (17), including the time 0 correction. Regression was performed on the expiratory C 2 H 2 data from breath number three onward. The C 18 O signal was used for application of the Sackner time 0 correction on Q c and Vti.
[See Verbanck and Paiva (20) for equations and details.] Heart rate (HR) was determined from the ECG signal over the time interval corresponding to the rebreathing maneuver. From Q c and HR, we determined SV. DL CO was directly obtained from the C 18 O signal, according to Sackner (17) . Although DL CO was measured at two levels of O 2 (Table 1) , we only report the low O 2 data. Because of the limited number of in-flight data points, it was not possible to get a complete set of values for membrane diffusing capacity and capillary volume. The low-O 2 DL CO values were also divided by the mean alveolar volume (end-tidal volume plus half the rebreathing-bag volume) to give CO diffusing capacity per unit lung volume (K CO ).
Statistical methods. To study the time course of each parameter throughout the different stages in flight and postflight, we normalized data at each time for each subject by the preflight average value for that subject in the same way as was done for the SLS-1 data (15) . In this way, the preflight average of the four subjects is 100% by definition, and preflight SE reflect intrasubject measurement variability. In-flight and postflight SE corresponding to the average values of the four subjects are a combination of intrasubject measurement variability and intersubject variability in response at each stage of the study.
Statistical analysis was performed by using Systat version 5.0 (Systat, Evanston, IL). Data were grouped according to session (preflight, early in flight, late in flight, Rϩ2, Rϩ4, Rϩ9), using either all four subjects or a subset of only two subjects. Additionally, rebreathing results from all subjects were pooled into preflight, in-flight, and postflight data sets. In each case, a two-way analysis of variance was performed to test for differences between the chosen categories. Whenever In-flight, early, and late refer to measurements on in-flight mission days 1 or 2 and days 9 or 10, respectively (see MATERIALS AND METHODS). R ϩ 2, R ϩ 4, and R ϩ 9 are postflight sessions 2, 4, and 9 days, respectively, after return to Earth. http://jap.physiology.org/ F ratios were significant, post hoc pair wise comparisons were tested for significance with the Bonferroni adjustment. The P Ͻ 0.05 level was used as the criterion for significance. Table 2 lists the average preflight values of all measured parameters on the four subjects. All parameters except DL CO and K CO , where a change was expected, were not significantly different when computed from the rebreathing tests with low-O 2 or high-O 2 rebreathing gas and are obtained from four low-O 2 and four high-O 2 tests, i.e., eight data points (see Table 1 ). DL CO and K CO values in Table 2 are subject averages of the four preflight low-O 2 rebreathing tests. In general, preflight SE values were of the order of 2-3%, except for Vti which had an average preflight SE of 4.5%. Figures 1-4 show the changes of normalized averages (Ϯ SE) of all parameters in Table 2 as a function of time during and after a 10-day period of µG. The preflight data point (j at 100%) results from pooling all data from the two preflight experiment sessions and has an arbitrary time tag for clarity of representation. For in-flight and postflight sessions, intervals on the time axis are representative of the number of days separating the experiment sessions. All j symbols are the average results from the four subjects whenever rebreathing data were collected on all four subjects within 24 h of each other. This was the case for the late in-flight session and during all postflight experiment sessions. All n symbols represent the averages of rebreathing data from subjects 1 and 2 only. For the early in-flight sessions, these are the only data available. For late in flight, these are a subset of the rebreathing data available on all four subjects (Table  1) . We display the data in this manner to avoid statistically skewing results from differing subject populations.
RESULTS
FRC (Fig. 1) was reduced in flight compared with preflight, although this was no longer significant in four subjects measured late in flight. Based on data from subjects 1 and 2, FRC did not change in flight In-flight FRC trend (dotted line) was not significant (P Ͼ 0.1). Fig. 2 . Pulmonary tissue volume (Vti) behavior in microgravity and at 2, 4, and 9 days postflight (Rϩ2, Rϩ4, Rϩ9, respectively) compared with preflight baseline values. Averages Ϯ SE of subjects 1-4 (j) or subjects 1-2 (n) are expressed as %individual preflight average. # Significant differences of averages of all 4 subjects at any given time (j) with respect to their preflight average. In-flight Vti trend (dotted line) was not significant (P Ͼ 0.1). between the early and the late data collection sessions. Vti (Fig. 2) was unchanged early in flight compared with preflight (n ϭ 2), but by late in flight Vti showed a significant reduction of ϳ25% (n ϭ 4; P Ͻ 0.001). Postflight, Vti remained depressed through Rϩ9 but showed a trend toward a return to normal. Q c (Fig. 3A) was elevated early in flight (n ϭ 2) and returned to preflight control by late in flight. This was confounded by significant changes in HR (Fig. 3B) , which was depressed early in flight and significantly elevated on Rϩ2. SV (Fig. 3C) provides a clearer picture and shows a large (ϳ40%) increase early in flight, but SV is reduced by late in flight to a level not significantly different from preflight controls. Both DL CO (Fig. 4A ) and K CO (Fig. 4B) were significantly elevated in both the early and the late in-flight sessions and returned to baseline postflight. There was no apparent temporal change in either DL CO or K CO postflight.
DISCUSSION
This paper reports a set of cardiopulmonary parameters obtained during a sustained 10-day period of weightlessness aboard the Spacelab-D2 mission. The major difference between our experiments and previous measurements during spaceflight (15) is that, by using Fig. 3 . Averages Ϯ SE of subjects 1-4 (j) or subjects 1-2 (n) are expressed as %individual preflight average. A: cardiac output (Q c) behavior in microgravity and at 2, 4, and 9 days postflight (Rϩ2, Rϩ4, Rϩ9, respectively) compared with preflight baseline values. In-flight Q c trend (dotted line) was not significant (NS; P ϭ 0.06). B: heart rate (HR) behavior in microgravity and 2, 4 and 9 days postflight with respect to preflight baseline values. In-flight HR trend (dotted line) was significant (P Ͻ 0.05). C : stroke volume (SV) derived from Q c and HR in A and B. In-flight SV trend (dotted line) was significant (P Ͻ 0.05).
C 2 H 2 and CO in the rebreathing gas mixture, we were able to compute Vti. A Vti value of, say, 600 ml measured from soluble gas rebreathing (17, 20) comprises ϳ100 ml dry tissue, 100 ml capillary blood volume, and 400 ml extravascular fluid (2) . As such, its value in weightlessness could be increased by a cephalad fluid shift and/or interstitial pulmonary edema or could be decreased by a net loss of body fluid.
Although one might expect a Vti increase due to the fluid shift from the lower body compartments, this was clearly not the case for the two subjects studied after ϳ24 h of µG (Fig. 2) . A possible explanation is that the loss of body fluid counteracts, and therefore masks, the Vti increase that the cephalad fluid shift might have caused. A summary of data from Apollo and Skylab missions reported in a review by Norsk and Epstein (12) shows that decreases in total body mass start within the first day of spaceflight. In flight, the decreasing Vti trend did not reach significance for the subgroup of subjects 1 and 2 (dotted line between n, Fig. 2) . However, the decrease of the average Vti value for all four subjects late in flight with respect to the preflight baseline was found to be highly significant (P Ͻ 0.001) and considerably below baseline (a 25% decrease). Together with the late in-flight Vti data, the steady and consistent slow recovery toward preflight baseline Vti values during the 10-day period after the mission also supports a correlation between the decrease of Vti and the net loss of body fluids in µG. The temporal changes of Vti indeed mimic the body weight profiles summarized in Norsk and Epstein (12) . Unfortunately, we have too few data points to actually correlate Vti with body mass, because body mass measurements were performed neither onboard Spacelab-D2 nor during the Rϩ9 session. Nevertheless, in support of the relation between a Vti decrease and body fluid loss, we note the average body weight decrease of 2.5 kg between preflight and Rϩ2 and the average increase of 0.6 kg between Rϩ2 and Rϩ15 (i.e., the session where body weight was determined closest to and after Rϩ9).
The Vti derived from the C 2 H 2 rebreathing test has been used to assess clinically mild and even inapparent interstitial pulmonary edema in humans, with Vti values ranging from 100 to 200 ml/l of TLC (the corresponding Vti value for a group of normal subjects was 80 ml/l of TLC) (13). Permutt (14) hypothesized that subclinical pulmonary edema could develop on entry into the µG environment, and, if this were the case, it would be expected to increase Vti. The lack of an increase in Vti early in flight suggests that interstitial pulmonary edema does not occur as a result of exposure to µG. Nevertheless, we cannot totally exclude the possibility that a net fluid loss could have masked any potential factors contributing to Vti increase, such as the postulated interstitial pulmonary edema. Even if edema were to have occurred early in flight, the marked Vti decrease late in flight suggests that it must have resorbed later in flight. However, the hypothesis of time dependence in the occurrence and resorption of interstitial pulmonary edema is contradicted by the membrane diffusing-capacity data obtained in µG by Prisk et al. (15) . In particular, the increase in membrane diffusing capacity in µG and the absence of any dependence on time spent in flight over a 10-day flight, counters the suggestion that the in-flight time dependence of Vti could have been due to early edema and absence thereof late in flight. Taken together, these data suggest that interstitial pulmonary edema as a result of exposure to µG did not occur.
The changes that we observed suggest that, despite documented cephalad fluid shifts from the lower extremities (4, 9, 12), this fluid does not move to the gas-exchanging region of the lung. Such a conclusion is consistent with recent findings of the absence of a rise in central venous pressure (5) and with the finding that the pulmonary interstitium is up to 30 times less compliant than other body tissues with respect to fluid accumulation (11) . The transendothelial filtration coefficient and the Starling pressures (hydrostatic and osmotic pressure differences between capillary and interstitum) determine the rate and direction of fluid transfer. Increased capillary recruitment must be assumed to have increased the transendothelial filtration coefficient (11) , but this effect appears to be reversed by the combined influences of a loss of plasma water (12) and the low tissue compliance in the lung, the latter tending to increase the hydrostatic tissue pressure markedly for any given increase of tissue fluid volume. Thus, despite clear evidence of excessive fluid in the tissues of the upper body, as evidenced by puffy faces, increased tissue thickness (9), and increased pulmonary capillary blood volume and SV (15), the lungs do not develop interstitial pulmonary edema in µG.
The other cardiopulmonary parameters computed here were FRC, Q c, DL CO , and K CO , which can all be compared with recently reported data obtained during the Spacelab SLS-1 mission (7, 15) . For instance, the FRC decreases in µG shown in Fig. 1 are in good agreement with the 15% decrease reported by Elliott et al. (7): an 8% FRC decrease for the four subjects (j) and an average 16% FRC decrease for the subset of two subjects (n). Also consistent with the findings of Elliott et al. (7) is the fact that FRC did not show any adaptation effects between early and late in flight.
Q c increases early in flight and returns to 12% below baseline toward the end of the mission. Postflight Q c is not significantly different from 100% from Rϩ2 onward. The general pattern is compatible with the SLS-1 data (15) , except that the magnitude of the initial (ϳ24 h) increase was Ͻ50% the increase in Q c observed in SLS-1 (14% in D-2 vs. 35% in SLS-1). In both studies, Q c was no longer significantly different from preflight baseline value by the end of the mission and postflight. The impact of the different methods used for computation of Q c [namely, the methods of Sackner et al. (17) in D-2, the method of Ayotte et al. (3) in SLS-1, and the use of C 2 H 2 instead of N 2 O] are expected to be small, and the differences more likely reflect differences between the subject populations, especially with respect to the HR response. As in SLS-1, the SV pattern amplifies the behavior of Q c, with a more marked increase early in flight due to a combination of the 14% rise in Q c and a 19% decrease in HR. The initial change we observed in SV was 40%, which was also smaller than that seen during SLS-1 (15) . The overall pattern of change was also similar, with a SV that is not significantly different from baseline by the end of the mission.
Finally, the diffusing capacity results (DL CO and K CO ) coincide with the SLS-1 observations, namely that diffusing capacity increases in µG to a new steady-state level, supporting the concept of uniform capillary filling. Of particular interest is the fact that the techniques used in D-2 and SLS-1 were different, namely rebreathing vs. single-breath breath-hold test. The single-breath test was a vital capacity maneuver, with the measurement of CO uptake being essentially performed at TLC, where significantly negative intrathoracic pressures may have enhanced pulmonary capillary filling in µG. In contrast, the rebreathing maneuver used here (i.e., a breathing pattern with a baseline end-expiratory lung volume corresponding to FRC and a tidal volume of ϳ2 liters) effectively determines DL CO for a mean lung volume of approximately FRC ϩ 1 liter, providing more normal physiological conditions. Direct comparison of DL CO values between SLS-1 and D-2 is not possible. Two comparative studies (1, 16) exist where DL CO values have been measured in the same subjects at rest by using both the single-breath and the rebreathing technique. When comparing measurements performed at similar lung volumes, Adaro et al. (1) found that DL CO was 30% larger when measured by rebreathing compared with the single-breath method. However, Rose et al. (16) found no DL CO differences by using either technique at two selected lung volumes. The difference in volume at which DL CO is measured in the D-2 and SLS-1 study is a good reason to compare K CO instead, even though K CO itself is also known to depend on alveolar volume. In fact, Stam et al. (18) found K CO to increase by ϳ30% when performing the single-breath maneuver at 50% instead of 100% TLC. When deriving K CO from the DL CO values and alveolar volumes reported in Rose et al. (16) , K CO is found to be only 10% larger when performing the single-breath test or rebreathing test at approximately FRC ϩ 1.5 liters rather than near TLC. The results of Adaro et al. (1) and Stam et al. (18) both contribute to explain the 50% larger preflight K CO values in D-2 than in SLS-1. Nevertheless, the findings of Rose et al. (16) would have predicted smaller differences between SLS-1 and D-2 on purely technical grounds. Also, the slightly higher alveolar O 2 concentration (typically 20-25%) in D-2 with respect to SLS-1 (16-18%) is expected to have a small but counteracting effect on the quantitative discrepancy between K CO results obtained from both missions. Despite these methodological differences and any supposed physiological effects that might be induced, the results obtained in D-2 and SLS-1 are similar. Figure 4B shows that the 32% increase of K CO in response to µG was actually in quantitative agreement with Prisk et al. (15) , who found K CO increases ϳ25% without any significant difference between measurements performed at different stages of the mission.
Because we have not been able to subdivide DL CO into its components, capillary volume and membrane diffusing capacity (because of too few data points for each level of O 2 concentration), we cannot confirm the most important finding of the SLS-1 study, namely the increase of both these components in µG and, derived from it, the µG model suggesting more uniform capillary filling in µG. Nevertheless, by obtaining an increase of the low-O 2 DL CO with respect to preflight (with a good agreement when normalizing for alveolar volume, i.e., K CO ), at least one of the conditions leading up to this model was met. We might have expected to see an increase in Vti in µG due to the likely increase in pulmonary capillary volume, since Vti incorporates capillary blood volume. However, it is most probable that the Vti parameter obtained by rebreathing is not sufficiently sensitive to pick up a capillary blood volume increase on the order of only 20 ml (15) .
Reproducibility and variability of the results. Preflight SE in Q c and DL CO are shown for each subject in Table 2 and were Ͻ3%. This is comparable to the SE obtained in the SLS-1 study (15) , where approximately twice the number of preflight rebreathing tests could be used for analysis. Our coefficients of variation for Q c (8%), DL CO (6%), and Vti (12%) are close to typical values given in Jensen et al. (8) , i.e., Q c (7%), DL CO (6%), and Vti (10%), also obtained from small samples of rebreathing measurements.
We had relatively few repeated-measurement opportunities in flight, where only one set of measurements after ϳ24 h of µG could be made on two subjects and another set on all four subjects late in flight. The subsets of data from subjects 1 and 2 (Figs. 1-4 , n) were insufficient to be able to draw firm conclusions about temporal changes of any of the parameters recorded in flight. They nevertheless show that the observed trends are consistent with the temporal changes or the absence of change observed by Prisk et al. (15) .
In conclusion, using different hardware and different techniques, we showed in a separate population that the observations of a transient increase in SV, followed by a decline to near preflight levels over the course of ϳ1 wk of µG, were correct (15) . Similarly, a decrease in FRC was observed (7) that persisted for the duration of µG exposure. In particular, the rebreathing measurements of DL CO support the prior observation of greater uniformity in pulmonary capillary filling in µG. This is important, because the rebreathing technique we employed avoids questions regarding highly negative intrathoracic pressures that might occur during the TLC breath hold of the single-breath DL CO method. We measured Vti for the first time in µG. In contrast to our expectations, Vti was not increased during early exposure to µG. This suggests that the previously postulated interstitial pulmonary edema (14) likely does not occur. The further decrease in Vti with continued exposure to µG and the slow return toward normal during the recovery period after flight suggest that this measurement is much more closely related to total body fluid volume than to translocation of fluid into the thoracic cavity.
